Detail akcie Immunicum Rg online

Business Summary: Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Mendus AB (publ) revenues was not reported. Net loss increased 26% to SEK128.4M. Higher net loss reflects Research and development expenses increase of 9% to SEK101.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -SEK4.39 to -SEK2.64.